SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: twentyfirstcenturyfox who wrote (7808)10/7/2001 12:33:02 PM
From: Montana Wildhack  Read Replies (1) of 14101
 
Fox,

I would venture that we had a big clue about the state of
EU adherence to MRA regulations in the first May go round
when very few countries responded in time.

The EU simply does not feel constrained by their published
timelines.

We saw this consistency in the lack of timely responses
by October 02 and in the extreme amount of time taken in
an average arbitration case.

This is no different from a country, province, or
municipality and the wide divergence of properly enforcing
its own regulations. Witness the smoking bylaws in Toronto
which forced the city to admit it had nowhere near the
staff required to come anywhere close to enforcing its
own regulations effectively.

The reason I rail against beaurocracy so much isn't because
of the inefficiencies so much as the fact of the arbitrary
enforcement that hurts individuals by its inconsistency.

That is when government is not consistent in enforcement
of its regulations - it is fair to no one.

What is ludicrous in this instance is that DMX management
was completely unable to influence this outcome. They
were never invited to these meetings and had no access
to any forum. It would have been extremely inappropriate
for Dimethaid to contact anyone but the MCA.

This was a singular issue.

Britain approved a drug and acted as sole agent to complete
the MRA for that drug. 14 parties were involved each
representing a country. No one else was invited.

The unfair outcome of that is to Dimethaid, shareholders,
and the individuals who will not get Pennsaid for that
much longer.

What's not open to interpretation is the fact that Pennsaid
really does work and is the cheapest most effective way
to take an NSAID for localized joint pain. Pain. Not
discomfort.

Something the British newspapers recently started noticing
in evaluating Provalis going forward.

The billion dollar US market we have secured so far is
sufficient to push DMX towards $10 once those markets
start maturing (say 2 years).

That combined with the stragglers that will come over the
months, HC, the strong FDA comments and my continued belief
Pennsaid will not be rejected in any market it applies to,
and not lastely WF10 and the continued access to cash (at
a temporary cost to shareprice) - means I'm keeping my shares.

Would I buy as many as I have at this point? No. But at $4
with what is there will I sell? No.

Good luck everyone,

Wolf
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News